• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.一种新型的、强效且选择性的非甾体分子对盐皮质激素受体的拮抗作用模式。
J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.
2
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.二氢吡啶类化合物作为盐皮质激素受体拮抗剂的立体化学要求。
J Med Chem. 2010 May 27;53(10):4300-4. doi: 10.1021/jm1002827.
3
The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.L、N 和 T 型三钙通道阻滞剂苯磺酸氨氯地平作为核受体家族成员的盐皮质激素受体拮抗剂。
Eur J Pharmacol. 2010 Jun 10;635(1-3):49-55. doi: 10.1016/j.ejphar.2010.03.018. Epub 2010 Mar 20.
4
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).醛固酮受体配体结合域与强效和选择性非甾体阻滞剂依司吖醇酮(CS-3150)复合物的晶体结构。
FEBS Lett. 2020 May;594(10):1615-1623. doi: 10.1002/1873-3468.13746. Epub 2020 Feb 19.
5
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.一些已上市的二氢吡啶类钙通道阻滞剂具有盐皮质激素受体拮抗剂活性。
Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4.
6
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
J Med Chem. 2017 Apr 13;60(7):2629-2650. doi: 10.1021/acs.jmedchem.6b01065. Epub 2017 Jan 24.
7
Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists.新型 1,4-二氢吡啶衍生物作为盐皮质激素受体拮抗剂。
Int J Mol Sci. 2023 Jan 26;24(3):2439. doi: 10.3390/ijms24032439.
8
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.非奈利酮阻碍盐皮质激素受体的醛固酮依赖性核转运并阻止类固醇受体辅激活因子-1的基因组募集。
J Biol Chem. 2015 Sep 4;290(36):21876-89. doi: 10.1074/jbc.M115.657957. Epub 2015 Jul 22.
9
Structural basis of spirolactone recognition by the mineralocorticoid receptor.盐皮质激素受体识别螺内酯的结构基础。
Mol Pharmacol. 2007 Sep;72(3):563-71. doi: 10.1124/mol.107.036459. Epub 2007 Jun 14.
10
Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.BAY 94-8862 的发现:一种用于治疗心脏肾脏疾病的非甾体类盐皮质激素受体拮抗剂。
ChemMedChem. 2012 Aug;7(8):1385-403. doi: 10.1002/cmdc.201200081. Epub 2012 Jul 12.

引用本文的文献

1
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists.心血管-肾脏-代谢效应:甾体类和非甾体类盐皮质激素受体拮抗剂
Rev Cardiovasc Med. 2025 Jul 29;26(7):38690. doi: 10.31083/RCM38690. eCollection 2025 Jul.
2
The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment.非奈利酮在慢性肾脏病合并2型糖尿病综合管理中的作用以及对心力衰竭预防和治疗的意义。
Heart Fail Rev. 2025 May 31. doi: 10.1007/s10741-025-10520-3.
3
Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health-Insights from Randomized Controlled Trials.非奈利酮:第三代盐皮质激素受体拮抗剂及其对心血管健康的影响——来自随机对照试验的见解
J Clin Med. 2024 Oct 25;13(21):6398. doi: 10.3390/jcm13216398.
4
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.非奈利酮作为糖尿病肾病新型治疗选择的意义:一项范围综述,重点关注非奈利酮3期试验的心肾结局
Front Med (Lausanne). 2024 Jun 14;11:1384454. doi: 10.3389/fmed.2024.1384454. eCollection 2024.
5
Challenges in Diagnosing and Managing the Spectrum of Primary Aldosteronism.原发性醛固酮增多症谱系诊断与管理中的挑战
J Endocr Soc. 2024 Jun 4;8(7):bvae109. doi: 10.1210/jendso/bvae109. eCollection 2024 May 23.
6
Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation.代谢紊乱药物抑制小胶质细胞介导的神经炎症中的 CXCL10 分泌。
J Neuroimmunol. 2024 Jun 15;391:578364. doi: 10.1016/j.jneuroim.2024.578364. Epub 2024 May 3.
7
Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.新型非甾体类盐皮质激素拮抗剂对糖尿病患者心血管和肾脏的益处
Curr Cardiol Rep. 2023 Dec;25(12):1859-1864. doi: 10.1007/s11886-023-01998-0. Epub 2023 Nov 22.
8
Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms.理解和治疗糖尿病肾病的进展:聚焦于肾小管间质性炎症机制。
Front Endocrinol (Lausanne). 2023 Oct 4;14:1232790. doi: 10.3389/fendo.2023.1232790. eCollection 2023.
9
Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis.非奈利酮在慢性肾脏病和2型糖尿病患者中的疗效与安全性:一项系统评价和荟萃分析
Ann Med Surg (Lond). 2023 Aug 16;85(10):4973-4980. doi: 10.1097/MS9.0000000000001180. eCollection 2023 Oct.
10
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.非甾体类盐皮质激素受体拮抗剂非奈利酮与射血分数保留的心力衰竭。
Cardiovasc Diabetol. 2023 Jun 29;22(1):162. doi: 10.1186/s12933-023-01899-0.

本文引用的文献

1
Helix 3-helix 5 interactions in steroid hormone receptor function.类固醇激素受体功能中螺旋3与螺旋5的相互作用
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):279-85. doi: 10.1016/j.jsbmb.2008.03.018. Epub 2008 Mar 13.
2
Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats.一种用于测定大鼠给药化合物抗盐皮质激素活性的简化检测方法的开发。
J Pharmacol Toxicol Methods. 2008 Mar-Apr;57(2):155-60. doi: 10.1016/j.vascn.2008.01.002. Epub 2008 Feb 6.
3
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.一些已上市的二氢吡啶类钙通道阻滞剂具有盐皮质激素受体拮抗剂活性。
Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4.
4
Structural basis of spirolactone recognition by the mineralocorticoid receptor.盐皮质激素受体识别螺内酯的结构基础。
Mol Pharmacol. 2007 Sep;72(3):563-71. doi: 10.1124/mol.107.036459. Epub 2007 Jun 14.
5
Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism.盐皮质激素受体突变是肾性1型假性醛固酮增多症的主要病因。
Hum Mutat. 2007 Jan;28(1):33-40. doi: 10.1002/humu.20371.
6
Mineralocorticoid-receptor blockade, hypertension and heart failure.盐皮质激素受体阻断、高血压与心力衰竭
Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):4-5. doi: 10.1038/ncpendmet0016.
7
Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults.常染色体显性遗传性1型假性醛固酮减少症:发病机制、新生儿致死性证据及成人表型表达
J Am Soc Nephrol. 2006 May;17(5):1429-36. doi: 10.1681/ASN.2005111188. Epub 2006 Apr 12.
8
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.雄激素受体中甾体类配体容纳的结构基础。
J Biol Chem. 2005 Nov 11;280(45):37747-54. doi: 10.1074/jbc.M507464200. Epub 2005 Aug 29.
9
Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor.盐皮质激素受体激素结合特异性及共激活因子组装的结构与生化机制
Mol Cell. 2005 Aug 5;19(3):367-80. doi: 10.1016/j.molcel.2005.06.026.
10
A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor.盐皮质激素受体激活所需的配体介导氢键网络。
J Biol Chem. 2005 Sep 2;280(35):31283-93. doi: 10.1074/jbc.M504098200. Epub 2005 Jun 20.

一种新型的、强效且选择性的非甾体分子对盐皮质激素受体的拮抗作用模式。

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

机构信息

Department of Medicinal Chemistry, Bayer Schering Pharma AG, Global Drug Discovery, 42096 Wuppertal, Germany.

出版信息

J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.

DOI:10.1074/jbc.M110.131342
PMID:20650892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2943305/
Abstract

Limitations of current steroidal mineralocorticoid receptor (MR) antagonists have stimulated the search for a new generation of molecules. We screened for novel nonsteroidal compounds and identified MR antagonists derived from the chemical class of dihydropyridines. Chemical optimization resulted in BR-4628, which displays high in vitro and in vivo MR potency as well as selectivity with respect to the other steroid hormone receptors and the L-type calcium channel. Biochemical studies demonstrated that BR-4628 forms complexes with MR that do not promote the recruitment of transcriptional co-regulators. Docking experiments, using the crystal structure of the MR ligand-binding domain in an agonist conformation, revealed that BR-4628 accommodates in the MR ligand-binding cavity differently in comparison with the classical steroidal MR antagonists. An alanine scanning mutagenesis approach, based on BR-4628 docking, allowed identifying its anchoring mode within the ligand-binding cavity. Altogether, we propose that BR-4628 is a bulky antagonist that inactivates MR through a passive mechanism. It represents the prototype of a new class of MR antagonists.

摘要

目前甾体类盐皮质激素受体(MR)拮抗剂的局限性促使人们寻找新一代分子。我们筛选了新型非甾体化合物,并从二氢吡啶类化合物的化学类别中鉴定出 MR 拮抗剂。通过化学优化得到了 BR-4628,它在体外和体内均表现出高 MR 活性和选择性,相对于其他甾体激素受体和 L 型钙通道。生化研究表明,BR-4628 与 MR 形成复合物,不会促进转录共调节剂的募集。使用激动剂构象的 MR 配体结合域晶体结构进行对接实验表明,与经典甾体 MR 拮抗剂相比,BR-4628 在 MR 配体结合腔内的容纳方式不同。基于 BR-4628 对接的丙氨酸扫描诱变方法允许确定其在配体结合腔内的锚定模式。总的来说,我们提出 BR-4628 是一种通过被动机制失活 MR 的大型拮抗剂。它代表了一类新型 MR 拮抗剂的原型。